IRIX Iridex Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: IRIX

Price (delayed)

$0.7002

Market cap

$12.3M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.2

Enterprise value

$11.63M

?
Relative Growth: Rel. Growth: 25
Relative Strength: Rel. Strength: 7
Relative Valuation: Rel. Valuation: 39
Relative Profitability: Rel. Profitability: 28

Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides ...

Highlights
Iridex's debt has decreased by 21% YoY and by 6% from the previous quarter
The revenue has increased by 3.7% year-on-year
The EPS has increased by 39% YoY but it has decreased by 5% QoQ
The net income is up by 35% YoY but it is down by 8% QoQ
IRIX's equity is down by 40% year-on-year and by 23% since the previous quarter
The quick ratio has declined by 28% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.iridex.com
Peers: MDT NVS COO STAA

Key stats

What are the main financial stats of IRIX

IRIX stock price

How has the Iridex stock price performed over time
Intraday
-2.9%
1 week
-1.7%
1 month
-15.13%
1 year
-49.44%
YTD
-38.58%
QTD
-38.85%

Financial performance

How have Iridex's revenue and profit performed over time
Revenue
$51.57M
Gross profit
$18.53M
Operating income
-$2.78M
Net income
-$3.55M
Gross margin
35.9%
Net margin
-6.9%
Iridex's net margin has increased by 37% YoY but it has decreased by 11% from the previous quarter
The net income is up by 35% YoY but it is down by 8% QoQ
The operating margin rose by 24% year-on-year but it has declined by 6% since the previous quarter
IRIX's operating income is up by 21% year-on-year but it is down by 3.3% since the previous quarter

Price vs fundamentals

How does IRIX's price correlate with its fundamentals

Growth

What is Iridex's growth rate over time

Valuation

What is Iridex stock price valuation
P/E
N/A
P/B
3.35
P/S
0.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.23
The EPS has increased by 39% YoY but it has decreased by 5% QoQ
IRIX's equity is down by 40% year-on-year and by 23% since the previous quarter
The price to book (P/B) is 37% lower than the 5-year quarterly average of 5.5 and 20% lower than the last 4 quarters average of 4.3
The stock's price to sales (P/S) is 70% less than its 5-year quarterly average of 0.8 and 40% less than its last 4 quarters average of 0.4
The revenue has increased by 3.7% year-on-year

Efficiency

How efficient is Iridex business performance
Iridex's ROE has soared by 58% YoY but it has decreased by 23% from the previous quarter
The ROS has increased by 39% YoY but it has decreased by 10% QoQ
IRIX's return on invested capital is up by 32% year-on-year but it is down by 12% since the previous quarter
The company's return on assets rose by 28% YoY but it fell by 13% QoQ

Dividends

What is IRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IRIX.

Financial health

How did Iridex financials performed over time
Iridex's total assets is 15% higher than its total liabilities
The quick ratio has declined by 28% year-on-year and by 12% since the previous quarter
Iridex's total assets has decreased by 14% YoY and by 3.6% QoQ
Iridex's debt is 10% more than its equity
IRIX's equity is down by 40% year-on-year and by 23% since the previous quarter
Iridex's debt to equity has increased by 31% YoY and by 22% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.